Cargando…

Factors Influencing the Efficacy of Umbilical Cord Blood-Derived Cell Therapy for Perinatal Brain Injury

INTRODUCTION: We have previously described preclinical literature which supports umbilical cord blood-derived cell (UCBC) therapy as an efficacious treatment for perinatal brain injury. However, efficacy of UCBCs may be influenced by different patient population and intervention characteristics. OBJ...

Descripción completa

Detalles Bibliográficos
Autores principales: Purcell, Elisha, Nguyen, Timothy, Smith, Madeleine, Penny, Tayla, Paton, Madison C B, Zhou, Lindsay, Jenkin, Graham, Miller, Suzanne L, McDonald, Courtney A, Malhotra, Atul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10021495/
https://www.ncbi.nlm.nih.gov/pubmed/36847059
http://dx.doi.org/10.1093/stcltm/szad006
_version_ 1784908500552384512
author Purcell, Elisha
Nguyen, Timothy
Smith, Madeleine
Penny, Tayla
Paton, Madison C B
Zhou, Lindsay
Jenkin, Graham
Miller, Suzanne L
McDonald, Courtney A
Malhotra, Atul
author_facet Purcell, Elisha
Nguyen, Timothy
Smith, Madeleine
Penny, Tayla
Paton, Madison C B
Zhou, Lindsay
Jenkin, Graham
Miller, Suzanne L
McDonald, Courtney A
Malhotra, Atul
author_sort Purcell, Elisha
collection PubMed
description INTRODUCTION: We have previously described preclinical literature which supports umbilical cord blood-derived cell (UCBC) therapy as an efficacious treatment for perinatal brain injury. However, efficacy of UCBCs may be influenced by different patient population and intervention characteristics. OBJECTIVES: To systematically review the effects of UCBCs on brain outcomes in animal models of perinatal brain injury across subgroups to better understand the contribution of model type (preterm versus term), brain injury type, UCB cell type, route of administration, timing of intervention, cell dosage, and number of doses. METHODS: A systematic search of MEDLINE and Embase databases was performed to identify studies using UCBC therapy in animal models of perinatal brain injury. Subgroup differences were measured by chi(2) test where possible. RESULTS: Differential benefits of UCBCs were seen across a number of subgroup analyses including intraventricular hemorrhage (IVH) vs. hypoxia ischemia (HI) model (apoptosis white matter (WM): chi(2) = 4.07; P = .04, neuroinflammation-TNF-α: chi(2) = 5.99; P = .01), UCB-derived mesenchymal stromal cells (MSCs) vs. UCB-derived mononuclear cells (MNCs) (oligodendrocyte WM: chi(2) = 5.01; P = .03, neuroinflammation-TNF-α: chi(2) = 3.93; P = .05, apoptosis grey matter (GM), astrogliosis WM), and intraventricular/intrathecal vs. systemic routes of administration (microglial activation GM: chi(2) = 7.51; P = .02, astrogliosis WM: chi(2) = 12.44; P = .002). We identified a serious risk of bias and overall low certainty of evidence. CONCLUSIONS: Preclinical evidence suggests UCBCs to show greater efficacy in the injury model of IVH compared to HI, the use of UCB-MSCs compared to UCB-MNCs and the use of local administrative routes compared to systemic routes in animal models of perinatal brain injury. Further research is needed to improve certainty of evidence and address knowledge gaps.
format Online
Article
Text
id pubmed-10021495
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-100214952023-03-18 Factors Influencing the Efficacy of Umbilical Cord Blood-Derived Cell Therapy for Perinatal Brain Injury Purcell, Elisha Nguyen, Timothy Smith, Madeleine Penny, Tayla Paton, Madison C B Zhou, Lindsay Jenkin, Graham Miller, Suzanne L McDonald, Courtney A Malhotra, Atul Stem Cells Transl Med Concise Reviews INTRODUCTION: We have previously described preclinical literature which supports umbilical cord blood-derived cell (UCBC) therapy as an efficacious treatment for perinatal brain injury. However, efficacy of UCBCs may be influenced by different patient population and intervention characteristics. OBJECTIVES: To systematically review the effects of UCBCs on brain outcomes in animal models of perinatal brain injury across subgroups to better understand the contribution of model type (preterm versus term), brain injury type, UCB cell type, route of administration, timing of intervention, cell dosage, and number of doses. METHODS: A systematic search of MEDLINE and Embase databases was performed to identify studies using UCBC therapy in animal models of perinatal brain injury. Subgroup differences were measured by chi(2) test where possible. RESULTS: Differential benefits of UCBCs were seen across a number of subgroup analyses including intraventricular hemorrhage (IVH) vs. hypoxia ischemia (HI) model (apoptosis white matter (WM): chi(2) = 4.07; P = .04, neuroinflammation-TNF-α: chi(2) = 5.99; P = .01), UCB-derived mesenchymal stromal cells (MSCs) vs. UCB-derived mononuclear cells (MNCs) (oligodendrocyte WM: chi(2) = 5.01; P = .03, neuroinflammation-TNF-α: chi(2) = 3.93; P = .05, apoptosis grey matter (GM), astrogliosis WM), and intraventricular/intrathecal vs. systemic routes of administration (microglial activation GM: chi(2) = 7.51; P = .02, astrogliosis WM: chi(2) = 12.44; P = .002). We identified a serious risk of bias and overall low certainty of evidence. CONCLUSIONS: Preclinical evidence suggests UCBCs to show greater efficacy in the injury model of IVH compared to HI, the use of UCB-MSCs compared to UCB-MNCs and the use of local administrative routes compared to systemic routes in animal models of perinatal brain injury. Further research is needed to improve certainty of evidence and address knowledge gaps. Oxford University Press 2023-02-27 /pmc/articles/PMC10021495/ /pubmed/36847059 http://dx.doi.org/10.1093/stcltm/szad006 Text en © The Author(s) 2023. Published by Oxford University Press. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.
spellingShingle Concise Reviews
Purcell, Elisha
Nguyen, Timothy
Smith, Madeleine
Penny, Tayla
Paton, Madison C B
Zhou, Lindsay
Jenkin, Graham
Miller, Suzanne L
McDonald, Courtney A
Malhotra, Atul
Factors Influencing the Efficacy of Umbilical Cord Blood-Derived Cell Therapy for Perinatal Brain Injury
title Factors Influencing the Efficacy of Umbilical Cord Blood-Derived Cell Therapy for Perinatal Brain Injury
title_full Factors Influencing the Efficacy of Umbilical Cord Blood-Derived Cell Therapy for Perinatal Brain Injury
title_fullStr Factors Influencing the Efficacy of Umbilical Cord Blood-Derived Cell Therapy for Perinatal Brain Injury
title_full_unstemmed Factors Influencing the Efficacy of Umbilical Cord Blood-Derived Cell Therapy for Perinatal Brain Injury
title_short Factors Influencing the Efficacy of Umbilical Cord Blood-Derived Cell Therapy for Perinatal Brain Injury
title_sort factors influencing the efficacy of umbilical cord blood-derived cell therapy for perinatal brain injury
topic Concise Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10021495/
https://www.ncbi.nlm.nih.gov/pubmed/36847059
http://dx.doi.org/10.1093/stcltm/szad006
work_keys_str_mv AT purcellelisha factorsinfluencingtheefficacyofumbilicalcordbloodderivedcelltherapyforperinatalbraininjury
AT nguyentimothy factorsinfluencingtheefficacyofumbilicalcordbloodderivedcelltherapyforperinatalbraininjury
AT smithmadeleine factorsinfluencingtheefficacyofumbilicalcordbloodderivedcelltherapyforperinatalbraininjury
AT pennytayla factorsinfluencingtheefficacyofumbilicalcordbloodderivedcelltherapyforperinatalbraininjury
AT patonmadisoncb factorsinfluencingtheefficacyofumbilicalcordbloodderivedcelltherapyforperinatalbraininjury
AT zhoulindsay factorsinfluencingtheefficacyofumbilicalcordbloodderivedcelltherapyforperinatalbraininjury
AT jenkingraham factorsinfluencingtheefficacyofumbilicalcordbloodderivedcelltherapyforperinatalbraininjury
AT millersuzannel factorsinfluencingtheefficacyofumbilicalcordbloodderivedcelltherapyforperinatalbraininjury
AT mcdonaldcourtneya factorsinfluencingtheefficacyofumbilicalcordbloodderivedcelltherapyforperinatalbraininjury
AT malhotraatul factorsinfluencingtheefficacyofumbilicalcordbloodderivedcelltherapyforperinatalbraininjury